Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	4DMedical Limited
ABN	31 161 684 831

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Julian Bernard Kingsley Sutton
Date of last notice	22 November 2024

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and indirect	
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Vinegar Hill Partners Pty Ltd (an entity controlled by Julian Sutton)	
Date of change	15 January 2025	
No. of securities held prior to change	Direct: 297,786 ordinary shares 4,266,666 unquoted options with exercise price of \$1.20 and expiry date of 15 March 2027 910,150 unquoted options with exercise price of \$0.40 and expiry date of 1 March 2025 1,028,346 unquoted options with exercise price of \$0.40 and expiry date of 1 March 2025 60,147 unquoted options with a nil exercise price and expiry date of 30 June 2029	
	Indirect: 183,014 ordinary shares	

⁺ See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Class	Ordinary shares / options
Number acquired	60,147 ordinary shares
Number disposed	60,147 options
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil
No. of securities held after change	Direct: 357,933 ordinary shares 4,266,666 unquoted options with exercise price of \$1.20 and expiry date of 15 March 2027 910,150 unquoted options with exercise price of \$0.40 and expiry date of 1 March 2025 1,028,346 unquoted options with exercise price of \$0.40 and expiry date of 1 March 2025 Indirect: 183,014 ordinary shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buyback	Exercise of options

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A

 $[\]boldsymbol{+}$ See chapter 19 for defined terms.

Appendix 3Y Page 2 01/01/2011

Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – *Closed period

Were the interests in the securities or contracts detailed	No
above traded during a +closed period where prior written	
clearance was required?	
If so, was prior written clearance provided to allow the	N/A
trade to proceed during this period?	
If prior written clearance was provided, on what date was	N/A
this provided?	

01/01/2011 Appendix 3Y Page 3

⁺ See chapter 19 for defined terms.